Introduction
death, neutropenia, AML, thrombocytopenia, anemia, aggressive malignancy, CD33-positive AML, undifferentiated myeloblasts
NEUTROPENIA, THROMBOCYTOPENIA, ACUTE MYELOID LEUKEMIA, DNA DAMAGE, AML, ANEMIA
Acute myeloid leukemia (AML) is an aggressive malignancy characterized by rapid clonal expansion of undifferentiated myeloblasts, leading to anemia, neutropenia, and thrombocytopenia [Gemtuzumab ozogamicin (GO) is a CD33-directed antibody–drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. GO binds to CD33, an antigen expressed on most AML blast cells. Once bound, the GO–CD33 complex is internalized, and the cytotoxic component is released intracellularly, leading to DNA damage and cell death [GO is indicated in the United States for the treatment of newly diagnosed CD33-positive AML in adult and pediatric (≥ 1 month) patients, and for relapsed/refractory (R/R) CD33-positive AML in adult and pediatric (≥ 2 years) patients [The clinical efficacy of GO was originally established with 3 open-label, single-arm phase II studies of patients with AML in first relapse who received GO monotherapy consisting of 2 × 9 mg/mConsequently, GO is approved in a fractionated dose of 3 mg/m